Selected research
Market Outlook & Growth Opportunities
Global Plasma for Fractionation Market Outlook and Growth Opportunities 2026
Market perspective
The global Plasma for Fractionation market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Plasma for Fractionation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Plasma for Fractionation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Plasma for Fractionation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Plasma for Fractionation market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Plasma for Fractionation market include Biotest, BPL, CBPO, CSL, Grifols, Kedrion, LFB Group, Octapharma and Hualan Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Plasma for Fractionation market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Plasma for Fractionation and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Plasma for Fractionation revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Plasma for Fractionation market.
Plasma for Fractionation Segment by Company
Biotest
BPL
CBPO
CSL
Grifols
Kedrion
LFB Group
Octapharma
Hualan Bio
RAAS
Takeda
Plasma for Fractionation Segment by Type
Recovered Plasma
Source Plasma
Plasma for Fractionation Segment by Application
Albumin
Immune Globulin
Coagulation Factor
Others
Plasma for Fractionation Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Plasma for Fractionation status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Plasma for Fractionation key companies, revenue, market share, and recent developments.
3. To split the Plasma for Fractionation breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Plasma for Fractionation market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Plasma for Fractionation significant trends, drivers, influence factors in global and regions.
6. To analyze Plasma for Fractionation competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma for Fractionation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma for Fractionation and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma for Fractionation.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plasma for Fractionation industry.
Chapter 3: Detailed analysis of Plasma for Fractionation company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Plasma for Fractionation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Plasma for Fractionation in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Recovered Plasma
- Source Plasma
Applications
- Albumin
- Immune Globulin
- Coagulation Factor
- Others
Companies covered
- Biotest
- BPL
- CBPO
- CSL
- Grifols
- Kedrion
- LFB Group
- Octapharma
- Hualan Bio
- RAAS
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Plasma for Fractionation Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Plasma for Fractionation Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Plasma for Fractionation Market Dynamics
- 2.1 Plasma for Fractionation Industry Trends
- 2.2 Plasma for Fractionation Industry Drivers
- 2.3 Plasma for Fractionation Industry Opportunities and Challenges
- 2.4 Plasma for Fractionation Industry Restraints
3 Plasma for Fractionation Market by Company
- 3.1 Global Plasma for Fractionation Company Revenue Ranking in 2025
- 3.2 Global Plasma for Fractionation Revenue by Company (2021-2026)
- 3.3 Global Plasma for Fractionation Company Ranking (2024-2026)
- 3.4 Global Plasma for Fractionation Company Manufacturing Base and Headquarters
- 3.5 Global Plasma for Fractionation Company Product Type and Application
- 3.6 Global Plasma for Fractionation Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Plasma for Fractionation Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Plasma for Fractionation Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Plasma for Fractionation Market by Type
- 4.1 Plasma for Fractionation Type Introduction
- 4.1.1 Recovered Plasma
- 4.1.2 Source Plasma
- 4.2 Global Plasma for Fractionation Sales Value by Type
- 4.2.1 Global Plasma for Fractionation Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Plasma for Fractionation Sales Value by Type (2021-2032)
- 4.2.3 Global Plasma for Fractionation Sales Value Share by Type (2021-2032)
5 Plasma for Fractionation Market by Application
- 5.1 Plasma for Fractionation Application Introduction
- 5.1.1 Albumin
- 5.1.2 Immune Globulin
- 5.1.3 Coagulation Factor
- 5.1.4 Others
- 5.2 Global Plasma for Fractionation Sales Value by Application
- 5.2.1 Global Plasma for Fractionation Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Plasma for Fractionation Sales Value by Application (2021-2032)
- 5.2.3 Global Plasma for Fractionation Sales Value Share by Application (2021-2032)
6 Plasma for Fractionation Regional Value Analysis
- 6.1 Global Plasma for Fractionation Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Plasma for Fractionation Sales Value by Region (2021-2032)
- 6.2.1 Global Plasma for Fractionation Sales Value by Region: 2021-2026
- 6.2.2 Global Plasma for Fractionation Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Plasma for Fractionation Sales Value (2021-2032)
- 6.3.2 North America Plasma for Fractionation Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Plasma for Fractionation Sales Value (2021-2032)
- 6.4.2 Europe Plasma for Fractionation Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Plasma for Fractionation Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Plasma for Fractionation Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Plasma for Fractionation Sales Value (2021-2032)
- 6.6.2 South America Plasma for Fractionation Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Plasma for Fractionation Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Plasma for Fractionation Sales Value Share by Country, 2025 VS 2032
7 Plasma for Fractionation Country-level Value Analysis
- 7.1 Global Plasma for Fractionation Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Plasma for Fractionation Sales Value by Country (2021-2032)
- 7.2.1 Global Plasma for Fractionation Sales Value by Country (2021-2026)
- 7.2.2 Global Plasma for Fractionation Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.7.2 France Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.14.2 China Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.17.2 India Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Plasma for Fractionation Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Plasma for Fractionation Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Plasma for Fractionation Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Biotest
- 8.1.1 Biotest Company Information
- 8.1.2 Biotest Business Overview
- 8.1.3 Biotest Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.1.4 Biotest Plasma for Fractionation Product Portfolio
- 8.1.5 Biotest Recent Developments
- 8.2 BPL
- 8.2.1 BPL Company Information
- 8.2.2 BPL Business Overview
- 8.2.3 BPL Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.2.4 BPL Plasma for Fractionation Product Portfolio
- 8.2.5 BPL Recent Developments
- 8.3 CBPO
- 8.3.1 CBPO Company Information
- 8.3.2 CBPO Business Overview
- 8.3.3 CBPO Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.3.4 CBPO Plasma for Fractionation Product Portfolio
- 8.3.5 CBPO Recent Developments
- 8.4 CSL
- 8.4.1 CSL Company Information
- 8.4.2 CSL Business Overview
- 8.4.3 CSL Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.4.4 CSL Plasma for Fractionation Product Portfolio
- 8.4.5 CSL Recent Developments
- 8.5 Grifols
- 8.5.1 Grifols Company Information
- 8.5.2 Grifols Business Overview
- 8.5.3 Grifols Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.5.4 Grifols Plasma for Fractionation Product Portfolio
- 8.5.5 Grifols Recent Developments
- 8.6 Kedrion
- 8.6.1 Kedrion Company Information
- 8.6.2 Kedrion Business Overview
- 8.6.3 Kedrion Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.6.4 Kedrion Plasma for Fractionation Product Portfolio
- 8.6.5 Kedrion Recent Developments
- 8.7 LFB Group
- 8.7.1 LFB Group Company Information
- 8.7.2 LFB Group Business Overview
- 8.7.3 LFB Group Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.7.4 LFB Group Plasma for Fractionation Product Portfolio
- 8.7.5 LFB Group Recent Developments
- 8.8 Octapharma
- 8.8.1 Octapharma Company Information
- 8.8.2 Octapharma Business Overview
- 8.8.3 Octapharma Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.8.4 Octapharma Plasma for Fractionation Product Portfolio
- 8.8.5 Octapharma Recent Developments
- 8.9 Hualan Bio
- 8.9.1 Hualan Bio Company Information
- 8.9.2 Hualan Bio Business Overview
- 8.9.3 Hualan Bio Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.9.4 Hualan Bio Plasma for Fractionation Product Portfolio
- 8.9.5 Hualan Bio Recent Developments
- 8.10 RAAS
- 8.10.1 RAAS Company Information
- 8.10.2 RAAS Business Overview
- 8.10.3 RAAS Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.10.4 RAAS Plasma for Fractionation Product Portfolio
- 8.10.5 RAAS Recent Developments
- 8.11 Takeda
- 8.11.1 Takeda Company Information
- 8.11.2 Takeda Business Overview
- 8.11.3 Takeda Plasma for Fractionation Revenue and Gross Margin (2021-2026)
- 8.11.4 Takeda Plasma for Fractionation Product Portfolio
- 8.11.5 Takeda Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst